Dietary Rehabilitation in Severely Acutely Malnourished Children

NCT05009823 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1959

Last updated 2023-11-18

No results posted yet for this study

Summary

Severe acute malnutrition (SAM) is a life threatening condition and is defined by 1) a weight-for-height Z-score more than three standard deviations (SD) below the median based on the 2006 World Health Organization (WHO) growth standards, 2) a mid-upper arm circumference (MUAC) of less than 115 mm or 3) by the presence of nutritional edema. Signs such as edema, mucocutaneous changes, hepatomegaly, lethargy, anorexia, anemia, severe immune deficiency and rapid progression to mortality characterize a state commonly coined as "complicated SAM". Kwashiorkor is one of the forms of complicated SAM commonly distinguished by the unmistakable presence of bipedal edema. SAM results in high mortality rates of up to half a million child deaths annually. Undernourished children are at higher risk of mortality ranging from three-times more risk among children with moderate malnutrition to 10-times in SAM children compared to well-nourished children. Children with complicated SAM require inpatient treatment in specialized centers.

The "Rehabilitation and Nutritional Education Center" (CREN) is a specialized center in Burkina Faso receiving on average 10 SAM children per day. Recovery rate is lower than international standards; and adverse events and mortality remain strikingly high.

The main objective of this study is to assess the underlying risk factors affecting the effectiveness of the nutritional therapeutic treatment protocol for complicated SAM children under 5 years of age who have been referred to the CREN, at the Centre Hôspitalier Universitaire Souro, Bobo Dioulasso, Burkina Faso.

The specific objective of this study is to better understand underlying risk factors associated with a lower recovery rate and high mortality in complicated SAM children referred to CREN for inpatient care. Risk factors associated with poor response to a standard dietary treatment at any phase will be assessed retrospectively.

Conditions

  • Severe Acute Malnutrition
  • Kwashiorkor
  • Nutritional Edema
  • Marasmus

Interventions

DIETARY_SUPPLEMENT

Standard F75

F-75 contains 75 kcal and 0.9 g protein per 100 ml.

DIETARY_SUPPLEMENT

Alternative F75 With CMV

Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.

DIETARY_SUPPLEMENT

Alternative F75 Without CMV

Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.

DIETARY_SUPPLEMENT

F100

100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)

DIETARY_SUPPLEMENT

Standard F75 + RUTF

Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive

DIETARY_SUPPLEMENT

Alternative F75 with CMV + RUTF

Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase

DIETARY_SUPPLEMENT

Alternative F75 without CMV + RUTF

Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase

Sponsors & Collaborators

  • Institut de Recherche en Sciences de la Sante, Burkina Faso

    collaborator OTHER_GOV
  • University Hospital Sourô Sanou of Bobo Dioulasso (Burkina Faso)

    collaborator UNKNOWN
  • Centre Muraz

    collaborator OTHER
  • University Ghent

    lead OTHER

Principal Investigators

  • Stefaan De Henauw, Md. PhD · University Ghent

  • Souheila Abbeddou, MSc. PhD · University Ghent

  • Jerome Some, Md. PhD · Institut de Recherche en Sciences de la Sante, Burkina Faso

  • Bintou Sanogo, MSc. Md. · Centre Hospitalier Universitaire Souro, Bobo Dioulasso, Burkina Faso.

Eligibility

Min Age
0 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • Burkina Faso

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05009823 on ClinicalTrials.gov